JP6824888B2 - 筋肉の疾患および障害を治療するための方法および組成物 - Google Patents

筋肉の疾患および障害を治療するための方法および組成物 Download PDF

Info

Publication number
JP6824888B2
JP6824888B2 JP2017541619A JP2017541619A JP6824888B2 JP 6824888 B2 JP6824888 B2 JP 6824888B2 JP 2017541619 A JP2017541619 A JP 2017541619A JP 2017541619 A JP2017541619 A JP 2017541619A JP 6824888 B2 JP6824888 B2 JP 6824888B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
muscle
subject
elp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017541619A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018509395A5 (enExample
JP2018509395A (ja
Inventor
ゲオルゴポーロス，リン
アーノルド，スーザン
ジェームス バランス，デイヴット
ジェームス バランス，デイヴット
Original Assignee
フェーズバイオ ファーマシューティカルズ，インコーポレイテッド
フェーズバイオ ファーマシューティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フェーズバイオ ファーマシューティカルズ，インコーポレイテッド, フェーズバイオ ファーマシューティカルズ，インコーポレイテッド filed Critical フェーズバイオ ファーマシューティカルズ，インコーポレイテッド
Publication of JP2018509395A publication Critical patent/JP2018509395A/ja
Publication of JP2018509395A5 publication Critical patent/JP2018509395A5/ja
Application granted granted Critical
Publication of JP6824888B2 publication Critical patent/JP6824888B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2017541619A 2015-02-09 2016-02-09 筋肉の疾患および障害を治療するための方法および組成物 Active JP6824888B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562113943P 2015-02-09 2015-02-09
US62/113,943 2015-02-09
US201562145770P 2015-04-10 2015-04-10
US62/145,770 2015-04-10
US201562150679P 2015-04-21 2015-04-21
US62/150,679 2015-04-21
PCT/US2016/017102 WO2016130518A2 (en) 2015-02-09 2016-02-09 Methods and compositions for treating muscle disease and disorders

Publications (3)

Publication Number Publication Date
JP2018509395A JP2018509395A (ja) 2018-04-05
JP2018509395A5 JP2018509395A5 (enExample) 2019-03-07
JP6824888B2 true JP6824888B2 (ja) 2021-02-03

Family

ID=56614686

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017541619A Active JP6824888B2 (ja) 2015-02-09 2016-02-09 筋肉の疾患および障害を治療するための方法および組成物

Country Status (8)

Country Link
US (4) US10688156B2 (enExample)
EP (1) EP3256151B1 (enExample)
JP (1) JP6824888B2 (enExample)
CN (2) CN107427556B (enExample)
AU (1) AU2016219513B2 (enExample)
CA (1) CA2976038A1 (enExample)
ES (1) ES2822598T3 (enExample)
WO (1) WO2016130518A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9561262B2 (en) 2011-06-06 2017-02-07 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
EP3139949B1 (en) 2014-05-08 2020-07-29 Phasebio Pharmaceuticals, Inc. Compositions comprising a vip-elp fusion protein for use in treating cystic fibrosis
WO2016130518A2 (en) 2015-02-09 2016-08-18 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating muscle disease and disorders

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4132746A (en) 1976-07-09 1979-01-02 University Of Alabama, Birmingham Medical & Education Foundation Synthetic elastomeric insoluble cross-linked polypentapeptide
US4187852A (en) 1976-07-09 1980-02-12 The University Of Alabama Synthetic elastomeric insoluble cross-linked polypentapeptide
US4500700A (en) 1981-10-02 1985-02-19 The Board Of Trustees Of The University Of Alabama For The University Of Alabama In Birmingham Elastomeric composite material comprising a polypentapeptide having an amino acid of opposite chirality in position three
US4474851A (en) 1981-10-02 1984-10-02 The University Of Alabama In Birmingham Elastomeric composite material comprising a polypeptide
US4589882A (en) 1983-09-19 1986-05-20 Urry Dan W Enzymatically crosslinked bioelastomers
US4752638A (en) 1983-11-10 1988-06-21 Genetic Systems Corporation Synthesis and use of polymers containing integral binding-pair members
US4749647A (en) 1984-06-22 1988-06-07 Genetic Systems Corporation Polymerization-induced separation assay using recognition pairs
US4605641A (en) 1984-10-09 1986-08-12 Hoffmann-La Roche Inc. Synthetic vasoactive intestinal peptide analogs
US4734400A (en) 1984-10-09 1988-03-29 Hoffmann-La Roche Inc. Synthetic vasoactive intestinal peptide analogs
US4783523A (en) 1986-08-27 1988-11-08 Urry Dan W Temperature correlated force and structure development of elastin polytetrapeptides and polypentapeptides
US4870055A (en) 1986-04-17 1989-09-26 University Of Alabama At Birmingham Segmented polypeptide bioelastomers to modulate elastic modulus
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US4898926A (en) 1987-06-15 1990-02-06 The University Of Alabama At Birmingham/Research Foundation Bioelastomer containing tetra/penta-peptide units
US5496712A (en) 1990-11-06 1996-03-05 Protein Polymer High molecular weight collagen-like protein polymers
US5641648A (en) 1986-11-04 1997-06-24 Protein Polymer Technologies, Inc. Methods for preparing synthetic repetitive DNA
US5770697A (en) 1986-11-04 1998-06-23 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US5514581A (en) 1986-11-04 1996-05-07 Protein Polymer Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
US5830713A (en) 1986-11-04 1998-11-03 Protein Polymer Technologies, Inc. Methods for preparing synthetic repetitive DNA
US6184348B1 (en) 1986-11-04 2001-02-06 Protein Polymer Technologies Functional recombinantly prepared synthetic protein polymer
US5243038A (en) 1986-11-04 1993-09-07 Protein Polymer Technologies, Inc. Construction of synthetic DNA and its use in large polypeptide synthesis
US6018030A (en) 1986-11-04 2000-01-25 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US5773249A (en) 1986-11-04 1998-06-30 Protein Polymer Technologies, Inc. High molecular weight collagen-like protein polymers
US4939224A (en) 1987-02-26 1990-07-03 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
US4835252A (en) 1987-02-26 1989-05-30 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
US5606019A (en) 1987-10-29 1997-02-25 Protien Polymer Technologies, Inc. Synthetic protein as implantables
IL87055A (en) 1988-07-08 1994-06-24 Illana Gozes Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5234907A (en) 1989-06-30 1993-08-10 Hoffmann-La Roche Inc. Synthetic vasoactive intestinal peptide analogs
US5141924A (en) 1989-06-30 1992-08-25 Hoffmann-La Roche, Inc. Synthetic vasoactive intestinal peptide analogs
US5236904A (en) 1989-09-18 1993-08-17 Senetek, Plc Erection-inducing methods and compositions
US5447912A (en) 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
ATE114458T1 (de) 1990-03-27 1994-12-15 Bioelastics Res Ltd Bioelastomeres arzneimittelabgabesystem.
DE69101187T2 (de) 1990-06-26 1994-09-29 Sanwa Kagaku Kenkyusho Co VIP-Analogen und ihre Verwendung.
JPH07108232B2 (ja) 1990-10-09 1995-11-22 エム・ディ・リサーチ株式会社 ペプチド又は蛋白質の製造方法
US5235041A (en) 1990-12-28 1993-08-10 Protein Polymer Technologies, Inc. Purification of structurally ordered recombinant protein polymers
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5393602A (en) 1991-04-19 1995-02-28 Bioelastics Research Ltd. Superabsorbent materials and uses thereof
JPH05238950A (ja) 1991-04-22 1993-09-17 Sanwa Kagaku Kenkyusho Co Ltd 易吸収性ｖｉｐ製剤
US5958881A (en) 1991-04-25 1999-09-28 Korman; Louis Y. Composition containing VIP for injection and a method of enhancing visualization of tissues during medical procedures
AU656230B2 (en) 1991-10-11 1995-01-27 F. Hoffmann-La Roche Ag Cyclic vasoactive peptides
US5681816A (en) 1992-04-24 1997-10-28 Korman; Louis Y. Method of inducing temporary paralysis of the gastrointestinal tract during medical procedure
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5972883A (en) 1993-03-16 1999-10-26 Yeda Research And Development Co. Ltd. Method for the treatment of neurodegenerative diseases by administering VIP, an analogue, fragment or a conjugate thereof
US5545617A (en) 1993-11-12 1996-08-13 The Schepens Eye Research Institute, Inc. Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5900405A (en) 1994-01-24 1999-05-04 Bioelastics Research, Ltd. Polymers responsive to electrical energy
JPH10502333A (ja) 1994-04-07 1998-03-03 プロティーンニックス カンパニー バソアクティブ・インテスティナル・ポリペプチド
US5527610A (en) 1994-05-20 1996-06-18 The Uab Research Foundation Elastomeric polypeptide matrices for preventing adhesion of biological materials
US6004782A (en) 1995-04-14 1999-12-21 Bioelastics Research Ltd. Hyperexpression of bioelastic polypeptides
US5972406A (en) 1995-04-14 1999-10-26 Bioelastics Research Ltd. Bioelastomers suitable as food product additives
US5854387A (en) 1995-04-14 1998-12-29 Bioelastics Research, Ltd. Simple method for the purification of a bioelastic polymer
US5624711A (en) 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
US6037321A (en) 1995-05-03 2000-03-14 Biostar Inc. Fusion proteins comprising vasoactive intestinal peptide or PACAP
EP0851768B1 (en) 1995-09-01 2002-04-24 University of Washington Interactive molecular conjugates
US5702717A (en) 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
EP0879246B1 (en) 1996-02-09 2006-05-31 F. Hoffmann-La Roche Ag Synthesis of vip analog
DE69721548T2 (de) 1996-02-09 2004-04-01 Abbott Laboratories(Bermuda)Ltd. HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN
US6063061A (en) 1996-08-27 2000-05-16 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
US5816259A (en) 1997-01-13 1998-10-06 Rose; Samuel Method for the diagnosis and treatment of cancer by the accumulation of radioactive precipitates in targeted cells
US20020099003A1 (en) 1997-10-28 2002-07-25 Wilson Leland F. Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
EP1056413A4 (en) 1998-02-27 2003-08-20 Bioelastics Res Ltd INJECTABLE IMPLANTS FOR TISSUE ENHANCEMENT AND RESTORATION
US6998387B1 (en) 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
FR2776520B1 (fr) 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
ES2138561B1 (es) 1998-04-17 2000-07-01 Univ Madrid Complutense Uso de los peptidos vip y pacap en el tratamiento del shock endotoxico en mamiferos.
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US20020151458A1 (en) 1998-04-17 2002-10-17 Perez Gomariz Rosa Maria Method for treating and preventing septic shock with VPAC1R, VPAC2R and PAC1R agonists
US6200598B1 (en) 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
WO2000056774A1 (en) 1999-03-19 2000-09-28 Duke University Methods of using bioelastomers
US20090175821A1 (en) 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
CA2391448A1 (en) 1999-11-12 2001-05-17 Leo Rubin Use of vasoactive intestinal peptides and kits therefor
US6235264B1 (en) 1999-12-01 2001-05-22 General Electric Company Medical imaging method for characterizing tumor angiogenesis using polymeric contrast agents
JP2001161363A (ja) 1999-12-03 2001-06-19 Hisamitsu Pharmaceut Co Inc 新規な小胞体局在タンパク質およびそれを含む糖タンパク質異常症治療薬、並びに該タンパク質をコードするｄｎａおよびそれを含む糖タンパク質異常症治療のための遺伝子治療薬。
US6593394B1 (en) 2000-01-03 2003-07-15 Prosperous Kingdom Limited Bioactive and osteoporotic bone cement
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
WO2001060862A1 (en) 2000-02-18 2001-08-23 Dabur Research Foundation Vasoactive intestinal peptide analogs
ATE355304T1 (de) 2000-02-18 2006-03-15 Dabur Res Foundation Radiomarkierte vip-analoge zur diagnose und therapie
US6852834B2 (en) 2000-03-20 2005-02-08 Ashutosh Chilkoti Fusion peptides isolatable by phase transition
US20050255554A1 (en) 2000-03-20 2005-11-17 Ashutosh Chilkoti Fusion peptides isolatable by phase transition
BR0111562A (pt) 2000-06-16 2003-04-15 Lilly Co Eli Análogos de peptìdeo 1 semelhantes ao glucagon
CN1487952A (zh) 2000-11-28 2004-04-07 �ɶ����＼��ʵ���� 具有血管活性肠肽的生物学活性的用于治疗肺动脉和小动脉高压的化合物
DK1355942T3 (da) 2000-12-07 2008-11-17 Lilly Co Eli GLP-1-fusionsproteiner
US7259233B2 (en) 2000-12-13 2007-08-21 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
EP1542712A2 (en) 2001-06-01 2005-06-22 Eli Lilly And Company Glp-1 formulations with protracted time action
CA2455884C (en) 2001-08-15 2015-09-22 Justin R. Fallon Treatment of muscular dystrophies and related disorders
US7101843B2 (en) 2001-08-23 2006-09-05 Eli Lilly And Company Glucagon-like peptide-1 analogs
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
WO2003039577A1 (en) 2001-11-06 2003-05-15 Senju Pharmaceutical Co., Ltd. Remedies for dry eye and diseases associated with dry eye
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
CN1313149C (zh) 2002-06-10 2007-05-02 蒙杜生物科技安斯塔特实验室 具有血管活性肠肽的生物学活性的化合物在治疗结节病中的用途
KR20050067439A (ko) 2002-11-27 2005-07-01 이토햄 가부시키가이샤 펩티드 및 이를 포함하는 의약조성물
US20040234609A1 (en) 2003-05-14 2004-11-25 Collier Katherine D. Repeat sequence protein polymer active agent congjugates, methods and uses
PL1633391T3 (pl) 2003-06-03 2012-03-30 Novo Nordisk As Stabilizowane farmaceutycznie kompozycje peptydowe
CA2532135A1 (en) 2003-07-14 2005-01-20 Mondobiotech Laboratories Anstalt Biologically active substance of a vasoactive intestinal peptide for treating interstitial lung infections
WO2005014030A1 (en) 2003-07-24 2005-02-17 Lutz-Henning Block Method for treating lung diseases associated with ventilation-perfusion mismatches
US7928059B2 (en) 2004-02-24 2011-04-19 Wisconsin Alumni Research Foundation Use of neuropeptides for traumatic cartilage injury
US7776815B2 (en) 2004-02-24 2010-08-17 Wisconsin Alumni Research Foundation Use of neuropeptides for ligament healing
US20050203009A1 (en) 2004-03-12 2005-09-15 Bayer Pharmaceuticals Corporation VPAC1 selective antagonists and their pharmacological methods of use
WO2005097158A1 (en) 2004-03-29 2005-10-20 The Arizona Board Of Regents On Behalf Of The University Of Arizona Amphipathic glycopeptides
CA2567635A1 (en) 2004-05-21 2005-12-01 Eli Lilly And Company Selective vpac2 receptor peptide agonists
BRPI0511367B8 (pt) 2004-06-11 2021-05-25 Vectus Biosystems Ltd uso de uma composição,composição, uso de vip e/ou de um fragmento ativo do mesmo
EP1768686A4 (en) 2004-06-12 2007-11-14 Bayer Pharmaceuticals Corp PEGYLATION OF VASOACTIVE INTESTINAL PEPTIDE (VIP) / HYPOPHYDE-ADENYLATE CYCLASE-ACTIVATING PEPTIDE (PACAP) RECEPTOR 2 (VPAC2) AGONISTS AND METHOD OF USE
US20080085860A1 (en) 2004-08-18 2008-04-10 Eli Lilly And Company Selective Vpac2 Receptor Peptide Agonists
CA2576755A1 (en) 2004-08-18 2006-03-02 Eli Lilly And Company Selective vpac2 receptor peptide agonists
JP2008515437A (ja) 2004-10-08 2008-05-15 フォーブス メディ−テック（リサーチ） インコーポレーテッド 血管活性腸管ポリペプチド医薬品
WO2006078629A2 (en) * 2005-01-18 2006-07-27 Duke University In-situ crosslinkable elastin-like polypeptides for defect filling in cartilaginous tissue repair
US7723472B2 (en) 2005-02-28 2010-05-25 The Regents Of The University Of California Extracellular matrix binding chimeric proteins and methods of use thereof
US20070009602A1 (en) 2005-06-24 2007-01-11 Setton Lori A Direct drug delivery system based on thermally responsive biopolymers
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
BRPI0617740A2 (pt) 2005-10-26 2011-08-02 Lilly Co Eli agonistas seletivos peptìdicos do receptor vpac2, composição farmacêutica e uso dos referidos agonistas
US20100184651A1 (en) 2005-11-18 2010-07-22 Dabur Pharma Limited Targeted fusion proteins for cancer therapy
AU2006322656B2 (en) * 2005-12-09 2012-03-08 Vectus Biosystems Limited VIP fragments and methods of use
EP1971355B1 (en) 2005-12-20 2020-03-11 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US7709227B2 (en) 2006-01-04 2010-05-04 Phasebio Pharmaceuticals, Inc. Multimeric ELP fusion constructs
US8367626B2 (en) 2006-05-12 2013-02-05 Wisconsin Alumni Research Foundation Elastin-like polymer delivery vehicles
CN103230598A (zh) 2006-09-06 2013-08-07 费斯生物制药公司 融合肽治疗组合物
CA2687602C (en) 2007-05-21 2014-07-15 Res International Sarl Peptides with improved properties having the biological activity of vasoactive intestinal peptide (vip) and their use for the treatment of lung diseases
DE602008005596D1 (de) 2007-06-21 2011-04-28 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
BRPI0815416A2 (pt) 2007-08-15 2014-10-21 Amunix Inc Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
US20110207673A1 (en) 2007-11-20 2011-08-25 Ashutosh Chilkoti Methods and compositions for modulating drug-polymer architecture, pharmacokinetics and biodistribution
WO2009135184A2 (en) * 2008-05-01 2009-11-05 The Trustees Of Columbia University In The City Of New York Methods for treating and/or preventing cardiomyopathies by erk or jnk inhibition
JP2011526303A (ja) 2008-06-27 2011-10-06 デューク ユニバーシティ エラスチン様ペプチドを含む治療剤
US20110219462A1 (en) 2008-07-15 2011-09-08 Bayer Schering Pharma Aktiengesellschaft G-Protein Coupled Receptor 30 (GPR30) transgenic animals as a model for cardiovascular diseases
US9333235B2 (en) 2008-10-22 2016-05-10 Trustees Of Dartmouth College Combination therapy and kit for the prevention and treatment of cystic fibrosis
US8314239B2 (en) 2008-10-23 2012-11-20 Vertex Pharmaceutical Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US20110288001A1 (en) 2008-12-18 2011-11-24 Homayoun Sadeghi Biologically active proteins activatable by peptidase
MX366935B (es) * 2009-08-14 2019-07-31 Phasebio Pharmaceuticals Inc Peptidos intestinales vasoactivos modificados.
CN102883739B (zh) 2009-11-02 2015-11-25 图兰恩教育基金管理人 垂体腺苷酸环化酶激活多肽（pacap）的类似物和它们的应用方法
US20130116184A1 (en) 2010-04-02 2013-05-09 The Regents Of The University Of Michigan RFamide-Related Peptides and Methods Thereof
CN103260647A (zh) 2010-11-30 2013-08-21 伦敦健康科学中心研究公司 用于治疗心脏病的egfr拮抗剂
CA2826663A1 (en) 2011-02-07 2012-08-16 Mochida Pharmaceutical Co., Ltd. Therapeutic agent for diastolic congestive heart failure
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
US9561262B2 (en) 2011-06-06 2017-02-07 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
CA2846209C (en) 2011-08-24 2022-04-05 Phasebio Pharmaceuticals, Inc. Systemic sustained release formulation comprising elastin­like peptide repeating sequence and protein active agent
SG11201402661TA (en) 2011-11-28 2014-08-28 Phasebio Pharmaceuticals Inc Therapeutic agents comprising insulin amino acid sequences
EP2664326B1 (en) 2012-05-17 2017-11-01 I.E.R.F.C. European Institute for Cystic Fibrosis Research Combined therapy for cystic fibrosis
WO2013177428A1 (en) 2012-05-23 2013-11-28 Valerion Therapeutics, Inc. Methods for increasing muscle contractility
US10159741B2 (en) 2012-05-25 2018-12-25 National Cheng Kung University Methods and compositions comprising hyaluronan for enhancing bone marrow cell therapy
US9605186B2 (en) 2012-09-19 2017-03-28 Exxonmobil Chemical Patents Inc. Adhesive compositions of ethylene-based and propylene-based polymers
US20150290328A1 (en) 2012-11-20 2015-10-15 Phasebio Pharmaceuticals, Inc. Formulations of active agents for sustained release
EP2945643A4 (en) 2013-01-15 2017-04-26 Phasebio Pharmaceuticals, Inc. Therapeutic agents, compositions, and methods for glycemic control
EP3139949B1 (en) * 2014-05-08 2020-07-29 Phasebio Pharmaceuticals, Inc. Compositions comprising a vip-elp fusion protein for use in treating cystic fibrosis
JP7075757B2 (ja) * 2014-11-21 2022-05-26 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド 制御放出および持続的放出のためのｅｌｐ融合タンパク質
WO2016130518A2 (en) 2015-02-09 2016-08-18 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating muscle disease and disorders

Also Published As

Publication number Publication date
US20250332221A1 (en) 2025-10-30
CA2976038A1 (en) 2016-08-18
CN107427556B (zh) 2022-02-25
US20210069299A1 (en) 2021-03-11
US10688156B2 (en) 2020-06-23
WO2016130518A3 (en) 2016-09-15
EP3256151A2 (en) 2017-12-20
EP3256151B1 (en) 2020-08-05
EP3256151A4 (en) 2018-08-22
CN107427556A (zh) 2017-12-01
AU2016219513B2 (en) 2021-09-30
US11266719B2 (en) 2022-03-08
ES2822598T3 (es) 2021-05-04
AU2016219513A1 (en) 2017-08-17
CN114652817A (zh) 2022-06-24
WO2016130518A2 (en) 2016-08-18
HK1249402A1 (zh) 2018-11-02
US20180333467A1 (en) 2018-11-22
JP2018509395A (ja) 2018-04-05
US20220288170A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
US20250332221A1 (en) Methods and compositions for treating muscle disease and disorders
Tidball et al. Evolving therapeutic strategies for Duchenne muscular dystrophy: targeting downstream events
JP5792925B2 (ja) 過剰体重を防止または治療するためのオキシンソモジュリン
KR102253597B1 (ko) 듀켄씨 근이영양증의 치료에서의 폴리스타틴
Gardiner et al. Mesenteric vasoconstriction and hindquarters vasodilatation accompany the pressor actions of exendin-4 in conscious rats
ES2732077T3 (es) Método para tratar trastornos asociados con el receptor de melanocortina-4 en portadores heterocigotos
ES2247329T3 (es) Prevencion de muerte celular utilizando segmentos de proteinas fibrilares neurales.
JP6262661B2 (ja) 筋萎縮性側索硬化症治療剤
ES2892957T3 (es) Composiciones y métodos de modulación de la actividad de AT2R
JP7698251B2 (ja) 急性期脳梗塞患者における脳梗塞の症状を治療するための医薬
US20200000874A1 (en) Peptides and methods of treating dystrophy-related disorders using the same
EP2911686B1 (en) Peptides for preventing ischemic tissue injury
HK1249402B (en) Methods and compositions for treating muscle disease and disorders
WO2016144968A1 (en) Relaxin therapy for disorders of the diaphragm
ES2701444T5 (es) Usos de bremelanotida en una terapia para la disfunción sexual femenina
AU2018225163A1 (en) Peptides and methods of treating dystrophy-related disorders using the same
WO2025056188A1 (en) Relaxin medication
WO2025035186A1 (en) Peptide conjugates and uses thereof
Boyer et al. Engineered Cationic Interleukin-1 Receptor Antagonist Outperforms Anakinra at Joint Retention and Preventing IL-1-induced Cartilage Inflammation
JP2024519893A (ja) 変形性関節症の治療方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201027

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210113

R150 Certificate of patent or registration of utility model

Ref document number: 6824888

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250